UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported) July 5, 2007
OrganiTECH U.S.A. INC.
- --------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-22151 93-0969365
- --------------------------------------------------------------------------------
(State or other jurisdiction (Commission (IRS Employer
of incorporation) File Number) Identification No.)
Yoqneam Industrial Area, P.O. Box 700, Yoqneam 20692, Israel
- --------------------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code 972-4-959-0515
- --------------------------------------------------------------------------------
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
[_] Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Items
On July 2, 2007, the Registrant's shares of common stock par value $0.001
commenced trading on the NASD's over-the-counter Bulletin Board ("OTCBB") under
the symbol "ORGT" (ORGT.OB). The Company's common stock was previously trading
on the Pink Sheets.
CIBC World Markets filed form 15c2-11 with the National Association of
Securities Dealers (NASD) and has been approved to act as the exclusive
market-maker for the Registrant's stock for a period of 30 days. A
15c2-11demonstrates that the market-maker has undertaken due diligence for
review and approval by the NASD. Once the 30 day period has expired other
market-makers may file form 15c-211.
The information contained in this Current Report on Form 8-K contains certain
forward-looking statements within the meaning of the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995. Statements contained in
this report and on such exhibit that are not historical in nature are considered
to be forward-looking statements. They may include statements regarding our
expectations, hopes, beliefs, estimates, intentions or strategies regarding the
future. These may include statements that contain words such as "believe",
"expect", " anticipate", "intend", estimate", "should", and similar expressions
intended to connote future events and circumstances.
Investors are cautioned that all forward-looking statements involve risks and
uncertainties, and that actual results could differ materially from those
described in the forward-looking statements. The forward-looking statements
contained in this report and on such exhibit are made only as of the date
hereof. We do not assume any obligation to update any of these forward-looking
statements.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
OrganiTECH U.S.A., INC.
(Registrant)
Date July 5, 2007
By: /s/ Yaron Shalem
--------------------
Yaron Shalem
Chief Financial Officer